An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy

Yutaka Ohsawa, Tadashi Okada, Shin Ichiro Nishimatsu, Masatoshi Ishizaki, Tomohiro Suga, Masahiro Fujino, Tatsufumi Murakami, Makoto Uchino, Kunihiro Tsuchida, Sumihare Noji, Atsushi Hinohara, Toshiyuki Shimizu, Kiyoshi Shimizu, Yoshihide Sunada

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Skeletal muscle expressing Pro104Leu mutant caveolin 3 (CAV3 P104L) in mouse becomes atrophied and serves as a model of autosomal dominant limb-girdle muscular dystrophy 1C. We previously found that caveolin 3-deficient muscles showed activated intramuscular transforming growth factor beta (TGF-Β) signals. However, the cellular mechanism by which loss of caveolin 3 leads to muscle atrophy is unknown. Recently, several small-molecule inhibitors of TGF-Β type I receptor (TΒRI) kinase have been developed as molecular-targeting drugs for cancer therapy by suppressing intracellular TGF-Β1,-Β2, and-Β3 signaling. Here, we show that a TΒRI kinase inhibitor, Ki26894, restores impaired myoblast differentiation in vitro caused by activin, myostatin, and TGF-Β1, as well as CAV3 P104L. Oral administration of Ki26894 increased muscle mass and strength in vivo in wild-type mice, and improved muscle atrophy and weakness in the CAV3 P104L mice. The inhibitor restored the number of satellite cells, the resident stem cells of adult skeletal muscle, with suppression of the increased phosphorylation of Smad2, an effector, and the upregulation of p21 (also known as Cdkn1a), a target gene of the TGF-Β family members in muscle. These data indicate that both TGF-Β-dependent reduction in satellite cells and impairment of myoblast differentiation contribute to the cellular mechanism underlying caveolin 3-deficient muscle atrophy. TΒRI kinase inhibitors could antagonize the activation of intramuscular anti-myogenic TGF-Β signals, thereby providing a novel therapeutic rationale for the alternative use of this type of anticancer drug in reversing muscle atrophy in various clinical settings.

Original languageEnglish
Pages (from-to)1100-1114
Number of pages15
JournalLaboratory Investigation
Volume92
Issue number8
DOIs
Publication statusPublished - 01-08-2012

Fingerprint

Caveolin 3
Transforming Growth Factor beta Receptors
Muscular Atrophy
Muscular Dystrophies
Transforming Growth Factor beta
Phosphotransferases
Myoblasts
Skeletal Muscle
Limb-Girdle Muscular Dystrophies
Myostatin
Activins
Muscles
Adult Stem Cells
Muscle Weakness
Muscle Strength
Oral Administration
Up-Regulation
Cell Count
Phosphorylation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Ohsawa, Yutaka ; Okada, Tadashi ; Nishimatsu, Shin Ichiro ; Ishizaki, Masatoshi ; Suga, Tomohiro ; Fujino, Masahiro ; Murakami, Tatsufumi ; Uchino, Makoto ; Tsuchida, Kunihiro ; Noji, Sumihare ; Hinohara, Atsushi ; Shimizu, Toshiyuki ; Shimizu, Kiyoshi ; Sunada, Yoshihide. / An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. In: Laboratory Investigation. 2012 ; Vol. 92, No. 8. pp. 1100-1114.
@article{56652407e243478587851bb8d816772e,
title = "An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy",
abstract = "Skeletal muscle expressing Pro104Leu mutant caveolin 3 (CAV3 P104L) in mouse becomes atrophied and serves as a model of autosomal dominant limb-girdle muscular dystrophy 1C. We previously found that caveolin 3-deficient muscles showed activated intramuscular transforming growth factor beta (TGF-Β) signals. However, the cellular mechanism by which loss of caveolin 3 leads to muscle atrophy is unknown. Recently, several small-molecule inhibitors of TGF-Β type I receptor (TΒRI) kinase have been developed as molecular-targeting drugs for cancer therapy by suppressing intracellular TGF-Β1,-Β2, and-Β3 signaling. Here, we show that a TΒRI kinase inhibitor, Ki26894, restores impaired myoblast differentiation in vitro caused by activin, myostatin, and TGF-Β1, as well as CAV3 P104L. Oral administration of Ki26894 increased muscle mass and strength in vivo in wild-type mice, and improved muscle atrophy and weakness in the CAV3 P104L mice. The inhibitor restored the number of satellite cells, the resident stem cells of adult skeletal muscle, with suppression of the increased phosphorylation of Smad2, an effector, and the upregulation of p21 (also known as Cdkn1a), a target gene of the TGF-Β family members in muscle. These data indicate that both TGF-Β-dependent reduction in satellite cells and impairment of myoblast differentiation contribute to the cellular mechanism underlying caveolin 3-deficient muscle atrophy. TΒRI kinase inhibitors could antagonize the activation of intramuscular anti-myogenic TGF-Β signals, thereby providing a novel therapeutic rationale for the alternative use of this type of anticancer drug in reversing muscle atrophy in various clinical settings.",
author = "Yutaka Ohsawa and Tadashi Okada and Nishimatsu, {Shin Ichiro} and Masatoshi Ishizaki and Tomohiro Suga and Masahiro Fujino and Tatsufumi Murakami and Makoto Uchino and Kunihiro Tsuchida and Sumihare Noji and Atsushi Hinohara and Toshiyuki Shimizu and Kiyoshi Shimizu and Yoshihide Sunada",
year = "2012",
month = "8",
day = "1",
doi = "10.1038/labinvest.2012.78",
language = "English",
volume = "92",
pages = "1100--1114",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "8",

}

Ohsawa, Y, Okada, T, Nishimatsu, SI, Ishizaki, M, Suga, T, Fujino, M, Murakami, T, Uchino, M, Tsuchida, K, Noji, S, Hinohara, A, Shimizu, T, Shimizu, K & Sunada, Y 2012, 'An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy', Laboratory Investigation, vol. 92, no. 8, pp. 1100-1114. https://doi.org/10.1038/labinvest.2012.78

An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. / Ohsawa, Yutaka; Okada, Tadashi; Nishimatsu, Shin Ichiro; Ishizaki, Masatoshi; Suga, Tomohiro; Fujino, Masahiro; Murakami, Tatsufumi; Uchino, Makoto; Tsuchida, Kunihiro; Noji, Sumihare; Hinohara, Atsushi; Shimizu, Toshiyuki; Shimizu, Kiyoshi; Sunada, Yoshihide.

In: Laboratory Investigation, Vol. 92, No. 8, 01.08.2012, p. 1100-1114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy

AU - Ohsawa, Yutaka

AU - Okada, Tadashi

AU - Nishimatsu, Shin Ichiro

AU - Ishizaki, Masatoshi

AU - Suga, Tomohiro

AU - Fujino, Masahiro

AU - Murakami, Tatsufumi

AU - Uchino, Makoto

AU - Tsuchida, Kunihiro

AU - Noji, Sumihare

AU - Hinohara, Atsushi

AU - Shimizu, Toshiyuki

AU - Shimizu, Kiyoshi

AU - Sunada, Yoshihide

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Skeletal muscle expressing Pro104Leu mutant caveolin 3 (CAV3 P104L) in mouse becomes atrophied and serves as a model of autosomal dominant limb-girdle muscular dystrophy 1C. We previously found that caveolin 3-deficient muscles showed activated intramuscular transforming growth factor beta (TGF-Β) signals. However, the cellular mechanism by which loss of caveolin 3 leads to muscle atrophy is unknown. Recently, several small-molecule inhibitors of TGF-Β type I receptor (TΒRI) kinase have been developed as molecular-targeting drugs for cancer therapy by suppressing intracellular TGF-Β1,-Β2, and-Β3 signaling. Here, we show that a TΒRI kinase inhibitor, Ki26894, restores impaired myoblast differentiation in vitro caused by activin, myostatin, and TGF-Β1, as well as CAV3 P104L. Oral administration of Ki26894 increased muscle mass and strength in vivo in wild-type mice, and improved muscle atrophy and weakness in the CAV3 P104L mice. The inhibitor restored the number of satellite cells, the resident stem cells of adult skeletal muscle, with suppression of the increased phosphorylation of Smad2, an effector, and the upregulation of p21 (also known as Cdkn1a), a target gene of the TGF-Β family members in muscle. These data indicate that both TGF-Β-dependent reduction in satellite cells and impairment of myoblast differentiation contribute to the cellular mechanism underlying caveolin 3-deficient muscle atrophy. TΒRI kinase inhibitors could antagonize the activation of intramuscular anti-myogenic TGF-Β signals, thereby providing a novel therapeutic rationale for the alternative use of this type of anticancer drug in reversing muscle atrophy in various clinical settings.

AB - Skeletal muscle expressing Pro104Leu mutant caveolin 3 (CAV3 P104L) in mouse becomes atrophied and serves as a model of autosomal dominant limb-girdle muscular dystrophy 1C. We previously found that caveolin 3-deficient muscles showed activated intramuscular transforming growth factor beta (TGF-Β) signals. However, the cellular mechanism by which loss of caveolin 3 leads to muscle atrophy is unknown. Recently, several small-molecule inhibitors of TGF-Β type I receptor (TΒRI) kinase have been developed as molecular-targeting drugs for cancer therapy by suppressing intracellular TGF-Β1,-Β2, and-Β3 signaling. Here, we show that a TΒRI kinase inhibitor, Ki26894, restores impaired myoblast differentiation in vitro caused by activin, myostatin, and TGF-Β1, as well as CAV3 P104L. Oral administration of Ki26894 increased muscle mass and strength in vivo in wild-type mice, and improved muscle atrophy and weakness in the CAV3 P104L mice. The inhibitor restored the number of satellite cells, the resident stem cells of adult skeletal muscle, with suppression of the increased phosphorylation of Smad2, an effector, and the upregulation of p21 (also known as Cdkn1a), a target gene of the TGF-Β family members in muscle. These data indicate that both TGF-Β-dependent reduction in satellite cells and impairment of myoblast differentiation contribute to the cellular mechanism underlying caveolin 3-deficient muscle atrophy. TΒRI kinase inhibitors could antagonize the activation of intramuscular anti-myogenic TGF-Β signals, thereby providing a novel therapeutic rationale for the alternative use of this type of anticancer drug in reversing muscle atrophy in various clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84864464834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864464834&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2012.78

DO - 10.1038/labinvest.2012.78

M3 - Article

VL - 92

SP - 1100

EP - 1114

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 8

ER -